Physician profile
George Robert Nahas
NPI 1932465341
$364,002.89
in general payments reported to CMS, 2019-2025
34 companies · $101K in 2025
The $101K reported for 2025 was more than what 98% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,963 · 2020: $7,204 · 2021: $29K · 2022: $61K · 2023: $50K · 2024: $114K · 2025: $101K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $166K · Consulting Fee: $56K · Travel and Lodging: $33K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,630.00 |
| Consulting Fee | $55,958.19 |
| Travel and Lodging | $32,591.98 |
| Food and Beverage | $10,259.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $152,106.91 | 2019-2025 | Tecvayli, Darzalex, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $106,672.23 | 2019-2025 | Abecma, Reblozyl, Onureg |
| Celgene Corporation | $19,970.87 | 2019-2024 | Reblozyl, Abecma |
| Blueprint Medicines Corporation | $16,220.18 | 2022-2025 | Ayvakit |
| Pfizer INC. | $13,068.30 | 2023-2025 | |
| Genzyme Corporation | $12,616.64 | 2023-2025 | |
| Seagen INC. | $11,298.69 | 2019-2023 | Adcetris |
| Lilly USA, LLC | $5,647.27 | 2023-2025 | Jaypirca |
| Ipsen Biopharmaceuticals, INC | $5,303.96 | 2022 | |
| Janssen Scientific Affairs, LLC | $4,690.78 | 2022-2025 | Darzalex, Talvey, Tecvayli |
| Glaxosmithkline, LLC. | $4,240.09 | 2021-2025 | Ojjaara |
| Geron Corporation | $2,670.99 | 2025 | Imetelstat |
| Beigene USA, INC. | $2,423.96 | 2022-2023 | Brukinsa |
| Kite Pharma, INC. | $2,106.56 | 2022-2024 | Yescarta |
| Genentech USA, INC. | $1,524.88 | 2021-2024 | Venclexta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $842.45 | 2022-2025 | Clonoseq, Immunoseq |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Incyte Corporation | $436.22 | 2019-2023 | Jakafi |
| Amgen INC. | $376.70 | 2019-2024 | Kyprolis |
| Novartis Pharmaceuticals Corporation | $155.30 | 2019-2025 | |
| Legend Biotech USA INC. | $147.25 | 2025 | Carvykti |
| Genmab U.S., INC. | $137.29 | 2023 | Epkinly |
| Eli Lilly and Company | $133.79 | 2023 | |
| Epizyme, INC. | $131.08 | 2021 | |
| Astellas Pharma US INC | $129.26 | 2019-2023 | Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $50.14 | 2024-2025 | Iclusig, Ninlaro |
| Sobi, INC | $45.36 | 2023-2024 | |
| Secura Bio, INC. | $45.34 | 2025 | Copiktra |
| Jazz Pharmaceuticals INC. | $39.42 | 2019 | |
| Janssen Global Services, LLC | $38.59 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $34.93 | 2022 | |
| Rigel Pharmaceuticals, INC. | $28.24 | 2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $19.22 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Nahas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.